As a leading biomedical sciences hub at the heart of Asia, Singapore is the choice location for companies to develop and produce new products that better meet Asia’s healthcare needs. Companies benefit from our pro-business environment, infrastructure, talent and innovation ecosystem, as well as our proximity to the rest of Asia.

Companies like GlaxoSmithKline, MSD and Roche have based a range of commercial activities, including Supply Chain Management, Regulatory Affairs and Medical Affairs in Singapore.

Singapore is a leading location for best-in-class manufacturing plants, where innovative products are launched and produced. Industry leaders like Pfizer, Novartis, Sanofi, AbbVie and Amgen have global manufacturing hubs in Singapore for a wide range of products including Active Pharmaceutical Ingredients, drug products and biologics drug substances. Since 2014, we have also partnered the industry to develop new talent training programmes.

In the last 30 years, there have been no major observations by regulators like the FDA who regularly audit local facilities. This speaks to the quality and reliability of our infrastructure and workforce, boosting pharmaceutical investors’ confidence to expand their operations.

Even as drug discovery and development models evolve amid regulatory changes and challenging R&D productivity, our extensive and integrated research ecosystem continues to deliver impact and value to pharmaceutical companies. Here, firms can forge partnerships with key opinion leaders, institutes, emerging biotechs, as well as clinical and contract research organisations to rapidly advance pipeline assets.

S$4 billion in public sector research funding has been committed to the Health and Biomedical Sciences Domain.